Noven Pharmaceuticals Inc

Type: Company
Name: Noven Pharmaceuticals Inc
Nationality: United States
First reported Oct 22 2014 - Updated Oct 22 2014 - 1 reports

Highland pulls in $25M for night-dosed morning ADHD treatment

Highland Therapeutics, a Toronto-based company with delayed-release technology for ADHD treatment, brought in $25 million to push its lead candidates through mid- and late-stage trials and prepare for commercialization.Highland's technology, called Delexis, ... [Published Fierce Drug Delivery - Oct 22 2014]
First reported Oct 22 2014 - Updated Oct 22 2014 - 1 reports

Patent Issued for Transdermal Drug Delivery System for Diclofenac

By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Alexandria, Virginia, by NewsRx journalists, a patent by the inventors Houze, David (Miami, FL); Hantman, Samara (Miami, FL), filed on September 14, 2012, ... [Published Pharmacy Choice - Oct 22 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

Noven Pharmaceuticals, Inc. press release :Noven files patent infringement lawsuit against Actavis

The lawsuit was filed as a result of Actavis submitting an Abbreviated New Drug Application ("ANDA") to the U.S. Food and Drug Administration ("FDA") in which Actavis is seeking approval to market and sell a generic version of Brisdelle®Noven Pharmaceuticals, ... [Published Noodls - Oct 20 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

Noven Pharmaceuticals Inc. Files Patent Infringement Lawsuit Against Actavis

MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc. announced today that it has filed a lawsuit in the U.S. District Court of New Jersey against Actavis Laboratories FL, Inc., Actavis Pharma, Inc., Andrx Corp., and Actavis, Inc. (collectively, ... [Published BioSpace - Oct 17 2014]
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

Noven files patent infringement lawsuit against Actavis

Noven Pharmaceuticals has announced that it has filed a lawsuit in the U.S. District Court of New Jersey against Actavis Laboratories FL, Inc., Actavis Pharma, Inc., Andrx Corp., and Actavis, Inc. for infringement of certain Noven patents. ... [Published PBR - News - Oct 17 2014]
First reported Oct 14 2014 - Updated Oct 14 2014 - 1 reports

Noven Announces Publication of Exploratory Analyses from Pooled Phase 3 Results of the Effects of Brisdelle® (Paroxetine) Capsules on Weight and Sexual Function During Treatment of Vasomotor Symptoms Associated with Menopause

MIAMI and NEW YORK, Oct. 14, 2014 /PRNewswire/ -- Noven Pharmaceuticals, Inc., today announced the publication of data on the effects of low-dose mesylate salt of paroxetine (LDMP), marketed as Brisdelle® (paroxetine) capsules, 7.5 mg, in the October ... [Published PR Newswire: Health - Oct 14 2014]
First reported Oct 09 2014 - Updated Oct 09 2014 - 1 reports

10/9/14 - Noven Receives FDA Approval of a New Indication with a New Dose for Minivelle® Estradiol Transdermal System

By a News Reporter-Staff News Editor at Women's Health Weekly Noven Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a new indication with a new dose of Minivelle (estradiol transdermal system) for the prevention ... [Published Pharmacy Choice - Oct 09 2014]
First reported Oct 08 2014 - Updated Oct 08 2014 - 2 reports

Patent Application Titled "Transdermal Drug Delivery System with Overlay" Published Online

By a News Reporter-Staff News Editor at Biotech Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a patent application by the inventors Nguyen, Viet (Miami, FL); Liu, Puchun (Miami, FL); Dinh, Steven (Miami, FL), ... [Published Pharmacy Choice - Oct 08 2014]
First reported Oct 02 2014 - Updated Oct 03 2014 - 2 reports

Noven receives FDA new indication approval for Minivelle

News and views on the clinical trials industry Thursday, October 2, 2014 02:01 PMNoven Pharmaceuticals  has announced that the  FDA has approved a new indication with a new dose of Minivelle (estradiol transdermal system) for the prevention of postmenopausal ... [Published Center Watch - Oct 03 2014]
First reported Sep 27 2014 - Updated Sep 27 2014 - 1 reports

Bioequivalent estradiol patch approved for new indication dose

The FDA has approved a 33% smaller dose of the estradiol transdermal system for the prevention of postmenopausal osteoporosis, according to the manufacturer.Minivelle (estradiol transdermal system, Noven Pharmaceuticals) is bioequivalent to Vivelle (estradiol ... [Published Orthopedics Today - Sep 27 2014]
First reported Sep 24 2014 - Updated Sep 25 2014 - 3 reports

FDA approves Noven's new dose for Minivelle to prevent postmenopausal osteoporosis

The US Food and Drug Administration (FDA) has approved Noven Pharmaceuticals' new indication with a new dose of Minivelle (estradiol transdermal system) to prevent postmenopausal osteoporosis. ... [Published PBR - News - Sep 25 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 3 reports

Noven Appoints Krista Roberts as Vice President of Operations

MIAMI & NEW YORK--(BUSINESS WIRE)--Noven Pharmaceuticals, Inc. today announced the appointment of Krista Roberts as the company’s new Vice President of Operations. In this role, Roberts will be responsible for all Noven manufacturing and related operations, ... [Published Business Wire Health News - Jun 23 2014]

Quotes

...company with a proprietary drugdrug delivery technology and two late-stage products in development," CEO David Lickrish said in a statement. "Looking forward, we anticipate reaching a number of critical near-term milestones, including Phase III data for HLD-200."
In addition to obtaining background information on this patent, NewsRx editors also obtained the inventors' summary information for this patent: "The present invention is directed to a transdermal delivery system for an active substance. The active substance is diclofenac and/or its derivatives, and preferably one or more of its alkali and organic salts and its free acid. The system comprises a backing layer, preferably moisture permeable, and an adhesive matrix affixed thereto, and a release liner. The total adhesive matrix composition comprises, on a dry weight percentage from about 5% to about 20% of a matrix constituent, from about 5% to about 25% of one or more permeation enhancers, and from about 10% to about 40% of the active substance."
...and other psychiatric disorders," said Joel Lippman, M D , FACOG, Noven's executive vice resident –product development and chief medical officer. "Noven understands this may be an important factor when considering treatment for moderate to severe hot flashes and that these analyses, with their limitations, may help provide physicians with a better understanding of Brisdelle."
...women's menopausal health," said Joel Lippman, M D , FACOG, Noven's Executive Vice President - Product Development and Chief Medical Officer. "We're pleased that we now have an additional indication and the new dosage strength available for Minivelle to allow women and their doctors to individualize their treatment to best fit their needs."

More Content

All (40) | News (25) | Reports (0) | Blogs (15) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Highland pulls in $25M for night-dosed morning ... [Published Fierce Drug Delivery - Oct 22 2014]
Patent Issued for Transdermal Drug Delivery Sys... [Published Pharmacy Choice - Oct 22 2014]
Ospemifene benefited postmenopausal women with ... [Published Orthopedics Today - Oct 21 2014]
Noven Pharmaceuticals, Inc. press release :Nove... [Published Noodls - Oct 20 2014]
Noven Pharmaceuticals Inc. Files Patent Infring... [Published BioSpace - Oct 17 2014]
Noven files patent infringement lawsuit against... [Published PBR - News - Oct 17 2014]
Noven Files Patent Infringement Lawsuit Against... [Published Fort Mills Times - Oct 16 2014]
Noven Files Patent Infringement Lawsuit Against... [Published EON Manufacturing - Oct 16 2014]
Noven Files Patent Infringement Lawsuit Against... [Published EON Consumer - Oct 16 2014]
Noven Files Patent Infringement Lawsuit Against... [Published EON Communications - Oct 16 2014]
Noven Files Patent Infringement Lawsuit Against... [Published EON Science - Oct 16 2014]
Noven Files Patent Infringement Lawsuit Against... [Published Business Wire Science: Science News - Oct 16 2014]
Noven Files Patent Infringement Lawsuit Against... [Published Business Wire Communications News - Oct 16 2014]
Noven Files Patent Infringement Lawsuit Against... [Published Business Wire Manufacturing News - Oct 16 2014]
Noven Files Patent Infringement Lawsuit Against... [Published Business Wire Health News - Oct 16 2014]
Noven Files Patent Infringement Lawsuit Against... [Published Scottrade - Oct 16 2014]
Noven Announces Menopause Drug's Effects on Wei... [Published Drug Discovery and Development - Oct 15 2014]
Noven Announces Publication of Exploratory Anal... [Published PR Newswire: Health - Oct 14 2014]
10/9/14 - Noven Receives FDA Approval of a New ... [Published Pharmacy Choice - Oct 09 2014]
Weekly FDA Enforcement Report For Drugs 10/1/14 [Published Pharmaceutical Online - Oct 09 2014]
Patent Application Titled "Transdermal Drug Del... [Published Pharmacy Choice - Oct 08 2014]
Researchers Submit Patent Application, "Composi... [Published Pharmacy Choice - Oct 08 2014]
Noven receives FDA new indication approval for ... [Published Center Watch - Oct 03 2014]
Noven receives FDA approval for new indication ... [Published Individual.com - Oct 02 2014]
Bioequivalent estradiol patch approved for new ... [Published Orthopedics Today - Sep 27 2014]
FDA approves Noven's new dose for Minivelle to ... [Published PBR - News - Sep 25 2014]
Noven Receives FDA Approval of a New Indication... [Published Drugs.com - Sep 25 2014]
Noven Receives FDA Approval of a New Indication... [Published Stock Nod - Sep 24 2014]
Noven Receives FDA Approval of a New Indication... [Published Industrial Info Financials - Sep 24 2014]
Noven Receives FDA Approval of a New Indication... [Published PR Newswire: Policy & Public Interest - Sep 24 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Noven files patent infringement lawsuit against... [Published PBR - News - Oct 17 2014]
Noven Pharmaceuticals has announced that it has filed a lawsuit in the U.S. District Court of New Jersey against Actavis Laboratories FL, Inc., Actavis Pharma, Inc., Andrx Corp., and Actavis, Inc. for infringement of certain Noven patents. ...
Noven Files Patent Infringement Lawsuit Against... [Published EON Manufacturing - Oct 16 2014]
MIAMI & NEW YORK--(EON: Enhanced Online News)--Noven Pharmaceuticals, Inc. announced today that it has filed a lawsuit in the U.S. District Court of New Jersey against Actavis Laboratories FL, Inc., Actavis Pharma, Inc., Andrx Corp., and Actavis, Inc. ...
Noven Files Patent Infringement Lawsuit Against... [Published EON Consumer - Oct 16 2014]
MIAMI & NEW YORK--(EON: Enhanced Online News)--Noven Pharmaceuticals, Inc. announced today that it has filed a lawsuit in the U.S. District Court of New Jersey against Actavis Laboratories FL, Inc., Actavis Pharma, Inc., Andrx Corp., and Actavis, Inc. ...
Noven Files Patent Infringement Lawsuit Against... [Published EON Communications - Oct 16 2014]
MIAMI & NEW YORK--(EON: Enhanced Online News)--Noven Pharmaceuticals, Inc. announced today that it has filed a lawsuit in the U.S. District Court of New Jersey against Actavis Laboratories FL, Inc., Actavis Pharma, Inc., Andrx Corp., and Actavis, Inc. ...
Noven Files Patent Infringement Lawsuit Against... [Published EON Science - Oct 16 2014]
MIAMI & NEW YORK--(EON: Enhanced Online News)--Noven Pharmaceuticals, Inc. announced today that it has filed a lawsuit in the U.S. District Court of New Jersey against Actavis Laboratories FL, Inc., Actavis Pharma, Inc., Andrx Corp., and Actavis, Inc. ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.